New webinar series: Intellectual property rights in digital biotech
In a new know-how webinar series the Centre for Digital Life Norway wants to give researchers knowledge on intellectual property rights (IPR) in digital biotechnology. This is a challenging field that has not been extensively addressed yet, but is important to explore since some IP decisions should be made early.
The Centre for Digital Life Norway (DLN) is launching two webinars in the new know-how webinar series on intellectual property rights (IPR) in digital biotechnology. The aim of the webinars is to give an insight to the IPR-system with a special focus on the combination of biotech and software, and to raise awareness about IP options.
This is a challenging field that has not been extensively addressed. Both within the biotech field and within the fields of algorithms and machine learning there are however special patenting requirements to consider. IP may help establish frameworks for collaborations and sharing of insights with external partners. Some IP decisions should therefore preferably be made early.
The webinars are free and open to all researchers. See the programmes and sign up for one or both webinars:
- 15 April 9–10.30 AM – part 1:
IPR biotech and software – basic laws and regulations
- 22 April 9–10.30 AM – part 2:
Patenting and digital biotech – from biological insights to algorithmic solutions
Tailored to the needs of precision medicine and diagnostics projects in the centre
‘Together with patent examiners from the Norwegian Industrial Property Office (NIPO) and inspired by research projects in the centre within precision medicine and diagnostics, we will take a closer look at some of the challenges academic researchers and commercialisation ecosystems face within digital biotech’, says Beate Rygg Johnsen, senior adviser for innovation and industry collaboration in the centre.
‘We will especially take a closer look at the areas of insights gained from medical data, and advances made by adding algorithmic solutions and machine learning to medical data. Looking at patents granted by the European Patent Office (EPO), we will attempt to make the many options more concrete, and at the same time address some legal obstacles which should be considered before strategic decisions are made’, elaborate patent examiners at NIPO, Barbro Sæther and Laila Dahl.